Clinical trials: Eating Disorders
Obesity and Overweight
A Combined Mindfulness-diving Protocol on Emotional Eating in Obese Patients: A Prospective Randomized Study
The goal of this clinical trial is to learn if a combined minfulness-diving program has an impact on emotional eating in adults with obesity.
- Trial name
- OBEDIVE (NCT06882200)
- Testing
- A combined mindfulness and therapeutic scuba-diving protocol, Control group regular follow up in primary care
- Where
- France
- Volunteers
- 63 people
- Sponsor
- BATHYSMED
Anorexia Nervosa Restricting Type, Binge-Eating Disorder
A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders
The goal of this clinical trial is to learn if MDMA-assisted therapy and caregiver involvement are safe and effective in treating female participants with eating disorders.
- Trial name
- MED1 (NCT04454684)
- Testing
- Midomafetamine, Non-directive therapy, Therapy
- Sponsor
- Resilient Pharmaceuticals
Obesity; Overweight
Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects
The primary objective of this study is to assess the efficacy of ROSE-010 on food intake in female subjects with overweight and obesity.
- Trial name
- NCT06621017
- Testing
- ROSE-010 99 mcg, ROSE-010 150 mcg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rose Pharma Inc
Eating Disorders, Binge Eating
Study of Efficacy and Safety of WELT-ED for Eating Disorder (WCTP-ED-B-01)
The purpose of this clinical trial is to evaluate the safety and efficacy of a digital therapeutic device (WELT-ED) based on Cognitive Behavioral Therapy (CBT) for the treatment of eating disorders.
- Conditions
- Eating Disorders, Binge Eating, Binge-Eating Disorder
- Trial name
- NCT06294353
- Testing
- WELT-ED (CBT based DTx), Standard Treatment
- Where
- 2 sites in South Korea
- Volunteers
- 134 people
- Sponsor
- WELT corp
Diabetes Mellitus, Type 1
Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin
Reason for the study The participants have been diagnosed with type 1 diabetes and are being treated with standard insulin therapy.
- Trial name
- NCT07634770
- Testing
- oral insulin, subcutaneous insulin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Binge Eating Disorder
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
To evaluate maintenance of efficacy based on time to relapse between SPD489 (50 or 70mg) and placebo, as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by…
- Trial name
- NCT02009163
- Testing
- Lisdexamfetamine dimesylate
- Where
- 53 sites in United States, Canada and 3 more
- Volunteers
- 418 people
- Sponsor
- Shire
Eating Disorders
The Use of Smart Devices in Capturing Digital Biomarkers in Eating Disorders
This study aims to explore how smart devices can be used to monitor the health of individuals with eating disorders. Eating disorders are serious mental health conditions that impact both mental and physical health.
- Trial name
- NCT06544226
- Testing
- UH100
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- Univa Health
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in…
- Trial name
- NCT00042601
- Testing
- Pramlintide acetate
- Where
- Australia
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Obesity, Eating Disorders
Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients
The primary objective is to assess the effect of rimonabant compared to placebo on weight loss over a period of 6 months when prescribed with a mild hypocaloric diet in obese patients with binge eating disorder.
- Trial name
- NCT00481975
- Testing
- rimonabant (SR141716)
- Where
- 7 sites in United States, Finland and 5 more
- Volunteers
- 289 people
- Sponsor
- Sanofi
Binge Eating Disorder
Dasotraline Binge Eating Disorder Extension Study
Binge Eating Disorder Extension Study.
- Trial name
- NCT02684279
- Testing
- Dasotraline
- Where
- 57 sites in United States
- Volunteers
- 533 people
- Sponsor
- Sumitomo Pharma America, Inc.
Type 2 Diabetes Mellitus
Pilot Study to Assess Adherence to a Novel Eating System in Men and Women With Type 2 Diabetes Mellitus
The purpose of this pilot study is to assess adherence to a Novel Eating System (NES) with and without energy restriction.
- Trial name
- NCT00907075
- Testing
- NES With Energy Restriction, NES Without Energy Restriction
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Mondelēz International, Inc.
Obesity, Overweight
A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity
This study consists of two phases: Phase A and Phase B. Participants are being asked to participate in both phases. Phase A of this study is comparing two formulations of a study medicine called NNC0487-0111 for weight control in…
- Trial name
- NCT06478563
- Testing
- NNC0487-0111 (formulation D), NNC0487-0111 (formulation C)
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Binge-Eating Disorder
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol…
- Trial name
- ENGAGE (NCT06413433)
- Testing
- Solriamfetol 150 mg, Solriamfetol 300 mg
- Where
- 45 sites in United States
- Volunteers
- 450 people
- Sponsor
- Axsome Therapeutics, Inc.
Binge-eating Disorder
Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder
This study will check how and to whom Vyvanse is prescribed in Australia by retrospectively analyzing a prescription database with additional information provided by a physician survey.
- Trial name
- NCT04866043
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- Shire
Mental Health
An Evaluation of Innerview™, a Web-based Tool to Support the Integration of Mental Health in the Primary Care Setting
Innerview can address some of the challenges of integrating mental health and primary care by accurately and reliably collecting mental health evidence and activities directly from patients, and then organizing and automating…
- Trial name
- NCT02025647
- Where
- 5 sites in United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Pearson/Clinical Assessment
Binge Eating Disorder
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder
- Trial name
- NCT03107026
- Testing
- dasotraline 4mg, dasotraline 6mg
- Where
- 50 sites in United States
- Volunteers
- 491 people
- Sponsor
- Sumitomo Pharma America, Inc.
Binge Eating
An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.
The purpose of this study is to evaluate the effectiveness and tolerability of topiramate compared to placebo in patients with binge eating disorder receiving Cognitive Behavior Therapy (CBT)
- Trial name
- NCT00307619
- Testing
- topiramate
- Volunteers
- 73 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Feeding and Eating Disorders
A Dose Escalating Study to Assess the Safety and Tolerability of GT-001
Dose escalation study of GT-001
- Trial name
- NCT03490786
- Testing
- GT-001
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Gila Therapeutics, Inc.
Obesity, Binge-Eating Disorder
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
The purpose of this study is to evaluate the safety and effectiveness of topiramate compared to placebo in reducing the number of binge days in patients with moderate to severe binge-eating disorder associated with obesity.
- Trial name
- NCT00210808
- Testing
- topiramate
- Volunteers
- 407 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.